Literature DB >> 32860424

Are Seniors Dependent on Benzodiazepines? A National Clinical Survey of Substance Use Disorder.

Caroline Victorri-Vigneau1,2, Edouard-Jules Laforgue1,2,3, Marie Grall-Bronnec2,3, Morgane Guillou-Landreat1,3, Morgane Rousselet1,2,3, Marylène Guerlais1, Fanny Feuillet2, Pascale Jolliet1,2.   

Abstract

Benzodiazepines and Z-drugs, zolpidem and zopiclone, (BZD/Z) are used longer than recommended in the elderly population. However, to date, very few attempts have been made to evaluate dependence on BDZ/Z among the elderly population. We conducted a national multicentric observational prospective study aimed at evaluating the prevalence of and risk factors for dependence among elderly adults. Patients aged 65 or older who were treated with BZD/Z for at least 3 months were evaluated through clinical interviews that conformed to official Diagnostic and Statistical Manual of Mental Disorders (DSM) dependence criteria. Among the 1,024 patients included in the survey, 442 of 976 (45.3%) met the dependence criteria. In the multivariate logistic regression model, dependent patients were categorized as follows: younger (odds ratio (OR) = 0.97), living mostly alone (OR = 1.45), showing psychiatric problems (OR = 2.22), having additional treatments (other than BZD/Z; OR = 1.37), having long-lasting treatment (OR = 1.04), exhibiting significant relationship difficulties (OR = 1.96), committing transgressional behaviors to procure BZD/Z (OR = 2.70), and wanting to stop their consumption of BZD/Z (OR = 7.60). A latent class analysis, which was applied to sort out subgroups within dependent patients, identified two profiles according to the prevalence of dependence items: profile 1 (73%), "withdrawal syndrome when BZD/Z is stopped" (100%) and "previous unsuccessful attempts to stop consumption" (82%); and profile 2 (27%), "tolerance" (76%) and "intake in larger amounts or over a longer period than intended" (86%). BZD/Z dependence is frequent in the elderly population, and among dependent patients, we found two profiles corresponding to positive and negative conditioning of the psychoactive effects of BZD/Z. This study is registered as NCT01920581.
© 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Year:  2020        PMID: 32860424     DOI: 10.1002/cpt.2025

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  3 in total

1.  Perception of the Regulatory Change for Zolpidem Prescription by French General Practitioners and Its Relation to Prescription Behavior.

Authors:  Edouard-Jules Laforgue; Marion Istvan; Benoit Schreck; Marie Mainguy; Pascale Jolliet; Marie Grall-Bronnec; Caroline Victorri-Vigneau
Journal:  J Clin Med       Date:  2022-04-13       Impact factor: 4.964

2.  Regulatory Framework Implementation for the Prescription of Zolpidem in France, What Impact in the Older People?

Authors:  Alexandra Jobert; Marion Istvan; Edouard-Jules Laforgue; Benoit Schreck; Caroline Victorri-Vigneau
Journal:  Int J Environ Res Public Health       Date:  2021-11-18       Impact factor: 3.390

3.  Did the New French Regulation of Zolpidem Decrease the Problematic Consumption of Zolpidem? A Field Study among Users.

Authors:  Edouard-Jules Laforgue; Morgane Rousselet; Antoine Claudon; Aurélie Aquizerate; Pascale Jolliet; Marion Istvan; Caroline Victorri-Vigneau
Journal:  Int J Environ Res Public Health       Date:  2022-07-22       Impact factor: 4.614

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.